Intrapleural 'outside-in' gene therapy

Therapeutics for organs of the chest via gene transfer to the pleura

Adriana Heguy, Ronald Crystal

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The pleural space is an attractive site for using viral vectors to deliver gene products to the lung parenchyma, other thoracic structures and the systemic circulation. The advantages of intrapleural gene transfer using viral vectors include: (i) easy accessibility; (ii) large surface area; (iii) ability to provide high concentrations of secreted gene products to chest structures; (iv) low risk of detrimental effects of possible vector-induced inflammation compared with intravascular delivery; and (v) because it is local, lower vector doses can be used to deliver therapeutic genes to thoracic structures than less efficient systemic routes. Examples of pleural gene transfer include the use of adenovirus vectors to treat mesothelioma by transiently expressing genes that encode toxic proteins, immunomodulatory molecules or anti-angiogenesis factors. Intrapleural delivery of adeno-associated viral vectors represents an efficient strategy to treat α1-antitrypsin (α1AT) deficiency, achieving high lung and systemic therapeutic levels of α1AT. Intrapleural delivery of gene transfer vectors holds promise for the treatment of diseases requiring transient, localized gene expression, as well as sustained expression of genes to correct hereditary disorders requiring localized or systemic expression of the therapeutic protein.

Original languageEnglish
Pages (from-to)440-453
Number of pages14
JournalCurrent Opinion in Molecular Therapeutics
Volume7
Issue number5
Publication statusPublished - 1 Oct 2005
Externally publishedYes

Fingerprint

Pleura
Genetic Therapy
Thorax
Genes
Therapeutics
Gene Expression
Lung
Angiogenesis Inducing Agents
Poisons
Mesothelioma
Adenoviridae
Proteins
Inflammation

Keywords

  • α-antitrypsin deficiency
  • Adeno-associated virus
  • Adenovirus
  • Gene therapy
  • Mesothelioma
  • Pleura

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Intrapleural 'outside-in' gene therapy : Therapeutics for organs of the chest via gene transfer to the pleura. / Heguy, Adriana; Crystal, Ronald.

In: Current Opinion in Molecular Therapeutics, Vol. 7, No. 5, 01.10.2005, p. 440-453.

Research output: Contribution to journalReview article

@article{27a0fd8e2b9f4ba6b1868a4391ef3b54,
title = "Intrapleural 'outside-in' gene therapy: Therapeutics for organs of the chest via gene transfer to the pleura",
abstract = "The pleural space is an attractive site for using viral vectors to deliver gene products to the lung parenchyma, other thoracic structures and the systemic circulation. The advantages of intrapleural gene transfer using viral vectors include: (i) easy accessibility; (ii) large surface area; (iii) ability to provide high concentrations of secreted gene products to chest structures; (iv) low risk of detrimental effects of possible vector-induced inflammation compared with intravascular delivery; and (v) because it is local, lower vector doses can be used to deliver therapeutic genes to thoracic structures than less efficient systemic routes. Examples of pleural gene transfer include the use of adenovirus vectors to treat mesothelioma by transiently expressing genes that encode toxic proteins, immunomodulatory molecules or anti-angiogenesis factors. Intrapleural delivery of adeno-associated viral vectors represents an efficient strategy to treat α1-antitrypsin (α1AT) deficiency, achieving high lung and systemic therapeutic levels of α1AT. Intrapleural delivery of gene transfer vectors holds promise for the treatment of diseases requiring transient, localized gene expression, as well as sustained expression of genes to correct hereditary disorders requiring localized or systemic expression of the therapeutic protein.",
keywords = "α-antitrypsin deficiency, Adeno-associated virus, Adenovirus, Gene therapy, Mesothelioma, Pleura",
author = "Adriana Heguy and Ronald Crystal",
year = "2005",
month = "10",
day = "1",
language = "English",
volume = "7",
pages = "440--453",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Intrapleural 'outside-in' gene therapy

T2 - Therapeutics for organs of the chest via gene transfer to the pleura

AU - Heguy, Adriana

AU - Crystal, Ronald

PY - 2005/10/1

Y1 - 2005/10/1

N2 - The pleural space is an attractive site for using viral vectors to deliver gene products to the lung parenchyma, other thoracic structures and the systemic circulation. The advantages of intrapleural gene transfer using viral vectors include: (i) easy accessibility; (ii) large surface area; (iii) ability to provide high concentrations of secreted gene products to chest structures; (iv) low risk of detrimental effects of possible vector-induced inflammation compared with intravascular delivery; and (v) because it is local, lower vector doses can be used to deliver therapeutic genes to thoracic structures than less efficient systemic routes. Examples of pleural gene transfer include the use of adenovirus vectors to treat mesothelioma by transiently expressing genes that encode toxic proteins, immunomodulatory molecules or anti-angiogenesis factors. Intrapleural delivery of adeno-associated viral vectors represents an efficient strategy to treat α1-antitrypsin (α1AT) deficiency, achieving high lung and systemic therapeutic levels of α1AT. Intrapleural delivery of gene transfer vectors holds promise for the treatment of diseases requiring transient, localized gene expression, as well as sustained expression of genes to correct hereditary disorders requiring localized or systemic expression of the therapeutic protein.

AB - The pleural space is an attractive site for using viral vectors to deliver gene products to the lung parenchyma, other thoracic structures and the systemic circulation. The advantages of intrapleural gene transfer using viral vectors include: (i) easy accessibility; (ii) large surface area; (iii) ability to provide high concentrations of secreted gene products to chest structures; (iv) low risk of detrimental effects of possible vector-induced inflammation compared with intravascular delivery; and (v) because it is local, lower vector doses can be used to deliver therapeutic genes to thoracic structures than less efficient systemic routes. Examples of pleural gene transfer include the use of adenovirus vectors to treat mesothelioma by transiently expressing genes that encode toxic proteins, immunomodulatory molecules or anti-angiogenesis factors. Intrapleural delivery of adeno-associated viral vectors represents an efficient strategy to treat α1-antitrypsin (α1AT) deficiency, achieving high lung and systemic therapeutic levels of α1AT. Intrapleural delivery of gene transfer vectors holds promise for the treatment of diseases requiring transient, localized gene expression, as well as sustained expression of genes to correct hereditary disorders requiring localized or systemic expression of the therapeutic protein.

KW - α-antitrypsin deficiency

KW - Adeno-associated virus

KW - Adenovirus

KW - Gene therapy

KW - Mesothelioma

KW - Pleura

UR - http://www.scopus.com/inward/record.url?scp=27144444044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144444044&partnerID=8YFLogxK

M3 - Review article

VL - 7

SP - 440

EP - 453

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 5

ER -